SCHEMBL4533849

SCHEMBL4533849

COc1ccc2cc(CN3CC(Oc4ccc(-c5ccc(S(C)(=O)=O)nc5)cc4)C3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.42
KCNH2 Q12809 3/20 0.42
PTGS2 P35354 1/20 0.39
LTA4H P09960 7/20 0.39
CNR1 P21554 1/20 0.39
FAAH O00519 1/20 0.39
PDE10A Q9Y233 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
PRKAA2 P54646 1/20 0.37
CYP19A1 P11511 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ACACB O00763 1/20 0.36
SLC2A1 P11166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348326 0.91 KCNH2 (0.50) MCHR1KCNH2PDE10AGPR119PRKAA2
SCHEMBL4349396 0.90 PRKAA2 (0.45) MCHR1KCNH2PRKAA2
SCHEMBL4351887 0.86 KCNJ1 (0.45) MCHR1KCNH2PDE10AGPR119PRKAA2
SCHEMBL3892630 0.85 NAAA (0.43) MCHR1KCNH2GPR119
SCHEMBL4352335 0.85 GBA1 (0.40) MCHR1KCNH2GPR119PRKAA2
SCHEMBL4345654 0.85 RORC (0.43) MCHR1KCNH2GPR119HRH3ACACB
SCHEMBL14403832 0.85 KCNH2 (0.41) MCHR1KCNH2GPR119PRKAA2HRH3
SCHEMBL2893346 0.85 HRH3 (0.37) MCHR1KCNH2GPR119HRH3ACACB
SCHEMBL2887199 0.85 KCNH2 (0.44) MCHR1KCNH2
SCHEMBL4353675 0.84 RORC (0.44) MCHR1KCNH2GPR119HRH3ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP claimed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US claimed
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists GPR119, GPR39, GIPR MCHR1 132/4885KCNH2 695/4885PTGS2 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.